The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Angiotensin Receptor Blockers (ARBs) Market Over The Period 2026–2030?
The market for angiotensin receptor blockers (arbs) has shown consistent expansion over recent years. This market is projected to grow from $8.78 billion in 2025 to $9.18 billion in 2026, at a compound annual growth rate (CAGR) of 4.6%. Several factors have contributed to this historical growth, including the rising prevalence of hypertension, increasing awareness of cardiovascular diseases, the expansion of hospital networks, the introduction of new arb molecules, and growing research efforts in kidney disease treatments.
The angiotensin receptor blockers (arbs) market is expected to show continuous expansion over the next few years. It is projected to reach $11.02 billion by 2030, achieving a compound annual growth rate (CAGR) of 4.7%. The anticipated growth during this period is driven by an aging population, increasing demand for personalized medicine, advancements in drug delivery systems, a rise in healthcare expenditure, and the expansion of specialty clinics. Key trends during the forecast period include personalized hypertension management, an increase in chronic kidney disease treatments, wider cardiovascular disease therapies, growing adoption of oral arb formulations, and a rise in prescriptions from hospitals and specialty clinics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
Which Major Factors Are Driving The Expansion Of The Angiotensin Receptor Blockers (ARBs) Market?
A growing prevalence of cardiovascular illnesses is anticipated to fuel the expansion of the angiotensin receptor blockers market in the future. Cardiovascular disease (CVD) encompasses any ailment impacting the heart or blood vessels, frequently linked to the accumulation of fatty deposits within the arteries (atherosclerosis) and an elevated risk of blood clots. Angiotensin receptor blockers work by reducing blood pressure and enhancing the heart’s ability to pump blood through their role in relaxing veins and arteries, which can lower the likelihood of cardiovascular disease. For instance, in January 2024, information from the American Heart Association, a US-based non-profit body, indicated that the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the rising occurrence of cardiovascular diseases is propelling the growth of the angiotensin receptor blockers market.
How Is The Angiotensin Receptor Blockers (ARBs) Market Divided Into Its Major Segments?
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
How Are Trends Transforming The Angiotensin Receptor Blockers (ARBs) Market Landscape?
Leading companies in the angiotensin receptor blocker market are advancing new products, such as angiotensin receptor neprilysin inhibitors, to improve treatment options and patient outcomes for cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) constitute a class of drugs utilized in the management of heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced sacubitril + valsartan tablets, specifically designed for treating heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination medication falls within the ARNI (angiotensin receptor neprilysin inhibitors) category. Sacubitril functions by enhancing the natriuretic peptide (NP) system, which helps alleviate fluid overload and promotes blood vessel dilation, while valsartan blocks the renin-angiotensin system (RAS) to reduce blood pressure and decrease the heart’s workload. Working in tandem, these elements effectively alleviate heart failure symptoms, lower the risk of cardiovascular mortality, and diminish the chances of hospitalization stemming from heart failure. They are available under the brand name Sacu V.
Who Are The Prominent Organizations Shaping The Angiotensin Receptor Blockers (ARBs) Market?
Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.
Read the full angiotensin receptor blockers (arbs) market report here:
Which Region Currently Holds The Largest Share Of The Angiotensin Receptor Blockers (ARBs) Market?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Angiotensin Receptor Blockers (ARBs) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp
Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Anti Hypertensive Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model